A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden.
作者信息
Jendle J, Buompensiere M I, Holm A L, de Portu S, Malkin S J P, Cohen O
机构信息
Institute of Medical Sciences, Örebro University, Campus USÖ, 701 82, Örebro, Sweden.
Medtronic International Trading Sàrl, Tolechenaz, Switzerland.
出版信息
Diabetes Ther. 2022 May;13(5):1125-1129. doi: 10.1007/s13300-022-01252-w. Epub 2022 Apr 11.
Abstract
摘要
相似文献
1
A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden.
Diabetes Ther. 2022 May;13(5):1125-1129. doi: 10.1007/s13300-022-01252-w. Epub 2022 Apr 11.
2
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden.
Diabetes Ther. 2021 Nov;12(11):2977-2991. doi: 10.1007/s13300-021-01157-0. Epub 2021 Oct 1.
3
Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands.
Adv Ther. 2023 May;40(5):2545-2548. doi: 10.1007/s12325-023-02431-2. Epub 2023 Mar 9.
4
Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Diabetes Technol Ther. 2019 Mar;21(3):110-118. doi: 10.1089/dia.2018.0328. Epub 2019 Feb 20.
5
Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes.
Diabetes Technol Ther. 2020 Nov;22(11):812-821. doi: 10.1089/dia.2020.0064. Epub 2020 Oct 19.
6
Letter to the Editor Regarding Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently-Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands.
Adv Ther. 2023 May;40(5):2542-2544. doi: 10.1007/s12325-023-02427-y. Epub 2023 Mar 9.
7
Cost-Effectiveness of Intermittently Scanned Continuous Glucose Monitoring Versus Advanced Hybrid Closed-Loop Systems in Type 1 Diabetes: Comment on Jendle et al.
Diabetes Ther. 2022 May;13(5):1121-1123. doi: 10.1007/s13300-022-01251-x. Epub 2022 Apr 11.
8
A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
Lancet. 2021 Jan 16;397(10270):208-219. doi: 10.1016/S0140-6736(20)32514-9.
9
Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece.
Diabetes Technol Ther. 2022 May;24(5):316-323. doi: 10.1089/dia.2021.0443.
10
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting.
Diabetes Technol Ther. 2024 May;26(5):324-334. doi: 10.1089/dia.2023.0455. Epub 2024 Mar 22.
引用本文的文献
1
Social disadvantage and technology use among adults with type 1 diabetes in Quebec: A cross-sectional study using data from the Canadian T1D (BETTER) Registry.
Diabetes Obes Metab. 2025 Jul;27(7):3921-3932. doi: 10.1111/dom.16426. Epub 2025 Apr 29.
2
Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands.
Adv Ther. 2023 May;40(5):2545-2548. doi: 10.1007/s12325-023-02431-2. Epub 2023 Mar 9.
本文引用的文献
1
Safety and Glycemic Outcomes During the MiniMed Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.
Diabetes Technol Ther. 2023 Nov;25(11):755-764. doi: 10.1089/dia.2023.0255. Epub 2023 Oct 25.
2
Cost-Effectiveness of Intermittently Scanned Continuous Glucose Monitoring Versus Advanced Hybrid Closed-Loop Systems in Type 1 Diabetes: Comment on Jendle et al.
Diabetes Ther. 2022 May;13(5):1121-1123. doi: 10.1007/s13300-022-01251-x. Epub 2022 Apr 11.
3
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users.
Diabetes Technol Ther. 2022 Feb;24(2):113-119. doi: 10.1089/dia.2021.0203.
4
Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
Lancet. 2021 Jun 12;397(10291):2275-2283. doi: 10.1016/S0140-6736(21)00789-3. Epub 2021 Jun 2.
5
Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
Diabetes Care. 2021 Apr;44(4):969-975. doi: 10.2337/dc20-2250. Epub 2021 Feb 12.
6
Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study.
Diabetes Technol Ther. 2021 Mar;23(S1):S35-S39. doi: 10.1089/dia.2020.0666.
7
Improving HbA1c Control in Type 1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two German Centres.
Diabetes Ther. 2021 Jan;12(1):363-372. doi: 10.1007/s13300-020-00978-9. Epub 2020 Dec 11.
8
Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial.
Diabetes Care. 2020 Dec;43(12):3024-3033. doi: 10.2337/dc20-1447. Epub 2020 Oct 14.
9
One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
Acta Diabetol. 2021 Feb;58(2):207-213. doi: 10.1007/s00592-020-01607-4. Epub 2020 Oct 12.
10
Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study.
Diabetes Care. 2020 Feb;43(2):389-397. doi: 10.2337/dc19-1610. Epub 2019 Dec 16.
Zotero 插件